By Ben Glickman
Arcutis Biotherapeutics received FDA approval for its Zoryve topical foam in the treatment of seborrheic dermatitis late Friday. The company said it plans to make the product widely available by the end of next month. Shares gained 31% to $3.19 after-hours.
Minerva Surgical will delist its shares from the Nasdaq, with the last day of trading on or about Dec. 28. The women’s health company expects the move to lower its general and administrative expenses. Shares fell 51% to $1.37 after-hours.
Enzo Biochem’s revenue in the quarter ended Oct. 31 rose 10% as it saw higher demand in multiple product areas. The company’s loss narrowed to $6.6 million, or 13 cents a share, from a loss of $10.6 million, or 22 cents a share, a year earlier. Shares rose 4.5% to $1.39 after-hours.
Write to Ben Glickman at [email protected]
Read the full article here
